Skip to content

Observational clinical study of Camrelizumab combined with apatinib in the treatment of advanced gastric cancer ------ open, multicenter, observational study

Observational clinical study of Camrelizumab combined with apatinib in the treatment of advanced gastric cancer ------ open, multicenter, observational study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059650
Enrollment
Unknown
Registered
2022-05-05
Start date
2022-04-29
Completion date
Unknown
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Case series:None

Sponsors

The First Affiliated Hospital of USTC West District
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age: = 18 years; 2. No gender limit; 3. Patients with advanced gastric cancer confirmed by histopathology or cytology; 4. ECOG score: 0-2 points; 5. The expected survival period is = 3 months; 6. Subjects volunteered to join the study, signed the informed consent form, had good compliance and cooperated with follow-up; 7. Researchers believe that treatment can benefit.

Exclusion criteria

Exclusion criteria: 1. Confirmed allergy to the test drug and/or its excipients; 2. 2. The subject has a history of immune deficiency disease or organ transplantation; 3. Pregnant or lactating women; 4. According to the investigator's judgment, patients are not suitable for inclusion in this study.

Design outcomes

Primary

MeasureTime frame
Progression-free survival;

Secondary

MeasureTime frame
Overall survival;Objective response rate;Disease control rate;

Countries

China

Contacts

Public ContactYifu He?Binghu

The First Affiliated Hospital of USTC West District

yifuhe@fsyy.ustc.edu.cn18963789042

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026